Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 44,804

Document Document Title
WO/2018/069763A1
The invention concerns a method for reducing or delaying the onset of irritation, discomfort, inflammation (acute or chronic), and/or an immune response at the ocular surface by topically administering a fluid comprising high molecular w...  
WO/2018/070521A1
In one embodiment, the present invention addresses the problem of: providing an agent for inhibiting a lectin pathway and an alternative pathway; and others. In one embodiment, the present invention relates to: a fusion polypeptide conta...  
WO/2018/069210A1
The compounds of a certain formula 1, in which R1, R2 and R3 have the meanings as given in the description, are novel effective inhibitors of phosphodiesterase type 4.  
WO/2018/069893A1
The present invention provides in one aspect methods for treating ocular diseases by administering pharmaceutical compositions comprising an inhibitor of colony stimulating factor-1 (CSF-1) receptors. In another aspect, the present inven...  
WO/2018/070390A1
The purpose of the present invention is to provide a pharmaceutical composition and the like used for treating or preventing angiogenic diseases. This pharmaceutical composition is a combination of a monoclonal antibody or antigen-bindin...  
WO/2018/069362A1
The invention provides novel compounds having the general formula (I), wherein R1, R1', R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2018/071619A1
The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositio...  
WO/2018/066651A1
An ophthalmic product which comprises: an ophthalmic composition that contains (A) a water-soluble polymer compound, (B) one or more surfactants selected from among polyoxyethylene hardened castor oils, polyoxyethylene sorbitan fatty aci...  
WO/2018/066676A1
The present invention addresses the problem of examining the physiological activity of selenoneine which is an organic selenium compound and thus finding novel uses thereof. To solve this problem, provided are a composition comprising an...  
WO/2018/066707A1
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...  
WO/2018/064164A1
Disclosed herein are methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct applic...  
WO/2018/060213A1
The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin r...  
WO/2018/059331A1
The present invention relates to a polyamide compound and a use thereof; specifically, the present invention relates to a type of polyamide compound (which preferably contains one or more amide bonds formed by the condensation of same or...  
WO/2018/059543A1
Use of a compound having the structure of formula A1 for the preparation of a medicament for treating an ocular disease, particularly a diabetes related ocular disease in a subject, wherein the ocular disease is selected from the group c...  
WO/2018/064354A1
The invention relates to compositions and methods for treating ophthalmic conditions.  
WO/2018/060212A1
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates...  
WO/2018/060282A1
The present invention provides a pharmaceutical composition comprising: a) a therapeutically effective amount of at least one cannabinoid receptor binding ligand, and b) a liquid vehicle comprising at least one semifluorinated alkane; as...  
WO/2018/055101A1
The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.  
WO/2018/056269A1
These eye drops contain (3S, 4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine-8-yl) -N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxylic acid amide or a salt thereof, and have a pH of 4.0 to 9.0.  
WO/2018/056268A1
Provided is an agent for the treatment and/or prevention of inflammatory eye disorder, containing (3S, 4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine-8-yl) -N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxylic acid amide or a salt th...  
WO/2018/058048A1
Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel aft...  
WO/2018/054932A1
The present invention provides a pharmaceutical composition comprising 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferable posterior blepharitis or...  
WO/2018/054489A1
The present invention provides a new therapeutic method for treating myopia progression by blocking cell growth in the retina using alpha-2-adrenergic receptor agonists or antagonists. The blockage will stop the progression of the myopia...  
WO/2018/053643A1
Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of...  
WO/2018/054077A1
The disclosure generally relates to methods of treating an ocular disease, comprising administering an effective amount of a pharmaceutical composition to an eye of a subject in need thereof, wherein the pharmaceutical composition compri...  
WO/2018/057588A1
Disclosed are chemical entities which are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, E, n and Z are as defined herein. These chemical entities are useful as inhibitors of the PAR-2 sig...  
WO/2018/057522A1
Pharmaceutical compositions are disclosed including an effective amount of a fusion protein that contains an anchor domain and a therapeutic polypeptide for use in treating a disorder that affects the eye (e.g., corneal haze or scarring,...  
WO/2018/052019A1
[Problem] To provide a visual function improvement agent or the like which is capable of effectively improving visual function, while being safe to ingest over the long term. [Solution] Nicotinamide mononucleotide is used as an active in...  
WO/2018/052053A1
The present invention pertains to a therapeutic agent for ophthalmic diseases which comprises a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in the form of nanopartic...  
WO/2018/047163A1
An ophthalmic composition useful for the treatment of bacterial eye infections is provided. The ophthalmic composition includes the suspension of particles of active anti-bacterial agent in a gelled matrix.  
WO/2018/047930A1
The purpose of the present invention is to provide a composition for preventing visual dysfunction resulting from exposure to light such as so-called blue light. According to the present invention, provided is a composition for preventin...  
WO/2018/047894A1
Provided is a novel antibody. According to the present invention, a monoclonal antibody or a binding fragment thereof binds to domain 3 of a human LAG-3, and has the properties described in (i) and (vi) and one or more of the properties ...  
WO/2018/047178A1
The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of...  
WO/2018/041563A1
The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes...  
WO/2018/043707A1
The purpose of the present invention is to provide an agent for regenerating a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function regenerating ability. The agent for ...  
WO/2018/043370A1
Provided is a novel medicine that suppresses apoptosis caused by a high osmotic pressure of lacrimal fluid. This dry eye therapeutic agent for suppressing apoptosis caused by high osmotic pressure of lacrimal fluid, contains (A) diclofen...  
WO/2018/045083A1
Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual ...  
WO/2018/039378A1
This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disub...  
WO/2018/036080A1
The invention provides an application of an amino adamantane mononitrate in preparing a drug for preventing and treating diseases such as glaucoma, vascular dementia, subarachnoid hemorrhage, pulmonary arterial hypertension, and the like...  
WO/2018/036522A1
A lanosterol compound ophthalmic preparation, a preparation method therefor and an application thereof in prophylaxis and treatment of ophthalmological diseases. The ophthalmic preparation contains a lanosterol compound at a concentratio...  
WO/2018/036523A1
An ophthalmic pharmaceutical composition containing an azole compound, a method for preparing the same, as well as a use of the pharmaceutical composition in the preparation of an ophthalmic preparation for preventing and treating ophtha...  
WO/2018/037581A1
[Problem] To provide a therapeutic agent for treating and/or improving retinopathy caused by glucose. [Solution] This therapeutic agent for retinopathy caused by glucose is characterized by having a sodium / glucose cotransporter 2 inhib...  
WO/2018/036942A1
The invention provides novel compounds having the general formula (I): (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X and R11 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2018/036498A1
Use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, in treating or inhibiting macular degeneration or age-related macular degeneration. And the...  
WO/2018/036957A1
The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R8, X, A and R11are as described herein, compositions including the compounds and methods of using the compounds as serine protease Htr...  
WO/2018/038966A1
The present invention provides a pharmaceutical composition comprising a formulation of a corticosteroid and at least one organic acid and, optionally, a fast-acting insulin analog, in a vehicle. Also provided are methods to induce the p...  
WO/2018/039545A2
Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 dom...  
WO/2018/034945A1
Methods are disclosed for treating and/or preventing retinal degeneration is a subject. In some embodiments, the method includes administering to the subject a therapeutically effective amount of a selective estrogen receptor modulator (...  
WO/2018/033854A1
The present invention relates to an improved ophthalmic aqueous composition containing tafluprost, to an improved ophthalmic aqueous composition containing tafluprost and timolol, and to a method for treating ocular hypertension and glau...  
WO/2018/033543A1
The present invention relates to methods of preventing or treating hearing loss and methods of preventing or inhibiting hair cell degeneration or hair cell death in a subject.  

Matches 1 - 50 out of 44,804